Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Early menopause is associated with higher cardiovascular disease (CVD) risk, but that does not show that hormone replacement therapy (HRT) prevents heart disease. NICE says not to offer HRT for primary or secondary CVD prevention. For menopause symptoms, the appropriate treatment depends on factors including a person’s cardiovascular risk, age, time since menopause, uterus status and preferred estrogen route—not on a universally “best” therapy.
What studies say about early menopause and cardiovascular risk
Early menopause is a cardiovascular risk marker in observational studies. Those studies find that certain cardiovascular outcomes are more common among women who experienced menopause early; they do not establish that HRT reduces those risks.
Pooled US cohort analysis
A 2021 analysis in Diabetes Care pooled data from 9,374 postmenopausal women in three US cohorts. After adjustment, early menopause was associated with higher risks of coronary heart disease (hazard ratio [HR] 1.11; 95% confidence interval [CI] 1.06–1.17), stroke (HR 1.11; 95% CI 1.06–1.17), atherosclerotic cardiovascular disease (HR 1.12; 95% CI 1.06–1.19) and heart failure (HR 1.09; 95% CI 1.03–1.16). These are relative associations, not an estimate of an individual’s absolute risk or proof of cause and effect.
MESA cohort
A 2012 study in Menopause analyzed 2,509 women aged 45–84 in the diverse US Multi-Ethnic Study of Atherosclerosis (MESA). Over a median follow-up of 4.78 years, early menopause was associated with coronary heart disease (HR 2.08; 95% CI 1.17–3.70) and stroke (HR 2.19; 95% CI 1.11–4.32). The analysis recorded 50 coronary heart disease events and 37 strokes, so the estimates come from relatively few events and have wide confidence intervals.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
What an international analysis adds—and cannot show
A 2021 analysis in Human Reproduction used individual data from 203,767 postmenopausal women across 10 studies. It reported lower CVD risk associated with HRT use among women with early surgical menopause. The analysis did not report HRT type or route, so it cannot establish which formulation, if any, accounts for the association or identify a best therapy. Nor does an observational association prove that HRT caused a reduction in risk.
Should HRT be used to prevent heart disease?
No. NICE’s 2024 guideline states: “Do not offer combined or oestrogen-only HRT for primary or secondary prevention of cardiovascular disease.” That recommendation distinguishes treating menopause symptoms from prescribing hormones to prevent a first cardiovascular event or prevent another one after a diagnosis.
Rank #2
Having early menopause may be a reason to discuss health risks and symptom treatment with a clinician, but the cohort findings above are not evidence that taking HRT will prevent CVD. HRT decisions should be based on the individual’s treatment goals and health profile.
How clinicians choose HRT for menopause symptoms
There is no single best HRT for everyone. Guidance emphasizes symptom relief, baseline cardiovascular and thromboembolic risk, age and time since menopause, estrogen route, and whether the person has a uterus.
Start with the reason for treatment and the person’s risk profile
Endocrine Society guidance advises assessing baseline CVD risk when considering menopausal hormone therapy. It suggests nonhormonal treatment for patients at high CVD risk. For patients at moderate CVD risk who are seeking hormone treatment for symptoms, it suggests transdermal estradiol as a first-line option. This is guidance for individualized symptom care, not a recommendation to use estrogen to prevent cardiovascular disease.
Consider estrogen route
Transdermal estradiol is delivered through the skin; oral estrogen is taken by mouth. The Endocrine Society identifies transdermal estradiol as a first-line option for moderate-CVD-risk patients seeking hormone treatment, and the British Menopause Society says transdermal estradiol is a route to consider for people with risk factors. These recommendations do not make transdermal estrogen a universal choice: a clinician should consider the person’s overall cardiovascular and thromboembolic risk and treatment needs.
Account for uterus status
For someone with a uterus, the Endocrine Society guidance pairs transdermal estradiol with micronized progesterone or another metabolically neutral progestogen. For someone without a uterus, its suggested transdermal approach is estrogen alone. The appropriate regimen still needs to be selected and reviewed with a clinician.
Set the dose and review plan individually
The British Menopause Society advises tailoring dose, regimen and duration to the individual and evaluating treatment annually. A prescription should therefore be treated as an ongoing clinical decision, not a fixed formula chosen from a list of “best” products.
Recommended Free Tools
What to discuss at a treatment appointment
- Purpose: Which symptoms are being treated, and what nonhormonal options are appropriate?
- Health profile: How do cardiovascular and thromboembolic risks affect the available choices?
- Timing: How old is the person, and how long has it been since menopause?
- Formulation: Is estrogen taken orally or transdermally, and is a progestogen needed based on uterus status?
- Follow-up: What dose and regimen are planned, and when will treatment be evaluated again?
NICE includes individualized discussion of HRT for people with early menopause aged 40–44. That discussion should address the person’s circumstances and treatment aims; it does not override NICE’s recommendation against using HRT for CVD prevention.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
